ClinicalTrials.Veeva

Menu
C

Capital Cardiology Associates | Albany, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Apixaban
Lorcaserin HCl
cholesterol
Inclisiran
Medication
Clopidogrel
BELVIQ
Retatrutide
Vupanorsen
sodium

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 15 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Boston Scientific logo
Bristol-Myers Squibb (BMS) logo
Novartis logo
Abbott logo
C
Eisai logo
Lilly logo
M
NYU Langone Health logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems